Enrollment in U.S. Pilot Study Evaluating Bioelectronic Device for Treatment of Rheumatoid Arthritis Completed
The primary purpose of this multi-center, randomized study is to evaluate safety and tolerability of SetPoint’s proprietary device, which is surgically placed on the vagus nerve. The study includes 14 subjects who had failed or were intolerant to multiple, mechanistically different, biologic therapies. Initial feedback from neurosurgeons performing the implantation has been positive. The company anticipates data readout in the first quarter of 2019.
SetPoint Medical Announces U.S. Pilot Trial to Evaluate First Bioelectronic Device to Treat Rheumatoid Arthritis
3/26/18: Trial assesses proprietary new device that delivers doses of electricity to treat rheumatoid arthritis; Builds on first-in-human data.
SetPoint Medical, a clinical-stage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, announced today the appointment of David Chernoff, MD as Chief Medical Officer. Dr. Chernoff is a molecular diagnostics and biopharmaceutical industry veteran who...